feed

S&P 500—

NASDAQ—

DOW—

VIX—

US10Y—

EUR/USD—

GOLD—

WTI—

BTC—

AArphraTerminal

Arphra/Issuer/VXL.V

VXL.V

Vaxil Bio Ltd.

HealthcareBiotechnologyCACADCountry macro →

$0.23

Jun 01, 2026

Revenue · FY

—

Net income

—

FY —

EPS · diluted

—

EBITDA

—

Explain this page

Arphra AIPlain-English read on Vaxil Bio Ltd.’s valuation

No ESG data on file

ESG disclosures for VXL.V aren't available yet — check back shortly.

Browse the cross-market ESG hub instead.